IgA antibodies against beta2 glycoprotein in hemodialysis patients are an independent risk factor for mortality

Cardiovascular complications are the most important cause of death in patients on dialysis with end-stage renal disease. Antibodies reacting with ?-glycoprotein I seem to play a pathogenic role in antiphospholipid syndrome and stroke and are involved in the origin of atherosclerosis. Here we evaluated the presence of anticardiolipin and anti-?-glycoprotein I antibodies together with other vascular risk factors and their relationship with mortality and cardiovascular morbidity in a cohort of 124 hemodialysis patients prospectively followed for 2 years. Of these, 41 patients were significantly positive for IgA anti-?-glycoprotein I, and the remaining had normal values. At 24 months, overall and cardiovascular mortality and thrombotic events were all significantly higher in patients with high anti-?-glycoprotein I antibodies. Multivariate analysis using Cox regression modeling found that age, hypoalbuminemia, use of dialysis catheters, and IgA ?-glycoprotein I antibodies were independent risk factors for death. Thus, IgA antibodies to ?-glycoprotein I are detrimental to the clinical outcome of hemodialysis patients.

Click below to read the article

This article is published in Kidney International

Read 2393 times

Last modified on Monday, 18 June 2012 12:49

Scroll to Top